TB Decision Support System - with RHINoVision


WHO Countries
USAID Focus Area
TB DIAH DSS
TB DIAH DSS
TB DIAH DSS
TB DIAH DSS
Priority Country Performance Analysis
TB DIAH DSS
TB DIAH DSS
Reach Indicators
TB DIAH DSS
TB DIAH DSS

This chart shows the number of rifampicin-resistant (RR)-, multidrug-resistant (MDR)-, and extreme drug-resistant- (XDR) TB cases diagnosed (lab-confirmed, clinically diagnosed, and extreme-drug resistant cases). The progressive increase in the number of MDR cases could be due to better reach and diagnosis of these cases and/or because of increase in number of RR- and MDR-TB cases. A comparison with the proportion of estimated MDR cases that are being diagnosed will indicate if the reach of diagnostic services is improving.

TB DIAH DSS
TB DIAH DSS

TB treatment coverage is the percentage of the estimated TB cases who have been detected and put on treatment regimens. The target is to detect and treat at least 90% of the estimated cases. The chart here shows the aggregate progress in TB treatment coverage in USAID's 24 priority countries against their combined estimated number of TB cases (all forms).

Drug Resistant TB Treatment Coverage

Year:

2017

Value:

33%

TB DIAH DSS

Reporting on RR-and MDR-TB cases started gradually among the 24 priority countries. By 2015, most of these countries were routinely reporting and treating identified RR- and MDR-TB cases. This chart shows the yearly trend of the percentage of the estimated cases of in the 24 priority countries who were put on treatment.

TB DIAH DSS
TB DIAH DSS

People living with HIV (PLHIV) are more likely to get infected and become sick with TB. In fact, TB is one of the leading causes of death among PLHIV. In cases of latent TB infection, HIV poses the strongest known risk for progressing to TB disease. Therefore, countries have adopted the strategy of testing HIV status among new and relapsed TB cases to rule out HIV co-infection or to provide the right treatment option. This chart shows the percentage of new and relapsed TB cases who have been tested for HIV infection with results documented.

TB DIAH DSS
TB DIAH DSS

Establishing a routine continuous surveillance system based on systematic drug susceptibility testing is critical for dealing with the scourge of the increasing MDR- and XDR-TB. This chart shows the percentage of new bacteriologically diagnosed and clinically diagnosed pulmonary and extrapulmonary TB cases who were tested for drug susceptibility, and thus, indicates progress toward achieving the routine continuous surveillance system for drug-resistant TB.

TB DIAH DSS
TB DIAH DSS
TB DIAH DSS
TB DIAH DSS
Cure Indicators
TB DIAH DSS
TB DIAH DSS

This chart indicates the number of TB cases successfully completed treatment, whether with bacteriologic evidence of success (cured) or without (treatment completed). This indicator is also a proxy measure of a program's capacity to retain patients through a complete course of chemotherapy with a favorable clinical result. There is a direct and immediate link between this outcome of treatment success and reduced TB mortality. This outcome is, in turn, influenced by a variety of factors (e.g., uninterrupted drug supply, supportive environment for the patient)

TB DIAH DSS
TB DIAH DSS

This chart compares the yearly trend of successfully treating cohorts of all forms of new and relapsed TB cases. This chart indicates the percentage of cases successfully treated among cohorts of new and relapsed TB cases. Cohort analysis is an important indicator of the quality of TB program and serves as a management tool to monitor the effectiveness of the national TB control program. This chart can be compared with the chart on "Number of TB cases treated successfully".

TB DIAH DSS
TB DIAH DSS

This chart indicates the percentage of all forms of MDR-TB cases successfully treated among cohorts of MDR-TB cases (all forms). This cohort analysis is an important indicator to monitor the effectiveness of the national TB control program. This chart can be used in conjunction with the chart on "Number of MDR-TB cases treated successfully" for better understanding of the quality of TB program.

TB DIAH DSS
TB DIAH DSS
Prevent Indicators

Percent TB Preventive Treatment among Children under-5

Year:

2017

Value:

23%

TB DIAH DSS
TB DIAH DSS
TB DIAH DSS

People living with HIV (PLHIV) are more likely to develop TB and it is the most common presenting illness among them. TB is one of the major cause of HIV-related deaths. Providing TB preventive therapy to PLHIV is a major strategy to reduce the burden of TB in PLHIV. This chart shows the number of PLHIV enrolled in clinical care who are on TPT. This number includes both those who are newly enrolled during the year and those who were currently enrolled in clinical care at the beginning of the corresponding year.

TB DIAH DSS
TB DIAH DSS
TB DIAH DSS
TB DIAH DSS
Commitment Indicators

Amount of funds government has made available for TB NTP by the total amount needed in the TB NTP on an annual basis

Year:

2018

Value:

67%

TB DIAH DSS

Amount of domestic financing for TB by the total amount of financing in a country

Year:

2018

Value:

41%

TB DIAH DSS

Government expenditures on essential TB program supplies during past year

Year:

2017

Value:

27442436

TB DIAH DSS

Financing Per TB Patient

Year:

2018

Value:

410

TB DIAH DSS

Percent Government expenditures on essential TB program supplies during past year

Year:

2017

Value:

6%

TB DIAH DSS

Percent of total funds required for NTP funded through domestic sources

Year:

2018

Value:

61%

TB DIAH DSS
TB DIAH Project Aggregates
Reach Indicators
IndicatorYearVariableDefinitionValue
Reach-12017c_newincTB Cases Notified (All Forms)4,110,204
Reach-12017newrel_m014+newrel_f014Pediatric TB cases Notified (Ages 0-14)347,915
Reach-1.22017newrel_m014Pediatric TB cases Notified: males aged 0-14 years180,526
Reach-1.32017newrel_f014Pediatric TB cases Notified: females aged 0-14 years167,389
Reach-1.42017priv_new_dxNew cases of TB diagnosed according to NTP treatment guidelines by private providers649,957
Reach-1.52017pub_new_dxNew cases of TB diagnosed according to NTP treatment guidelines by non NTP public providers445,373
Reach-22017conf_rrmdr+all_conf_xdrDrug Resistant TB Cases Notified97,892
Reach-22017conf_rrmdr_txNumber of laboratory-confirmed rifampicin-resistant (RR-TB) or multidrug-resistant TB (MDR-TB) patients who started treatment for MDR-TB78,878
Reach-22017conf_xdr_txNumber of laboratory-confirmed XDR-TB patients who started treatment for XDR-TB5,475
Reach-22017unconf_rrmdr_txNumber of patients (not laboratory-confirmed as having rifampicin-resistant (RR-TB) or multidrg-resistant TB (MDR-TB)) who started treatment for MDR-TB1,082
Reach-22017conf_rrmdrNumber of laboratory-confirmed RR-TB or MDR-TB cases identified92,468
Reach-22017all_conf_xdrNumber of laboratory-confirmed XDR-TB cases identified in the current year (including in MDR cases diagnosed in previous years)5,424
Reach-32017(c_newinc)/(e_inc_num)TB Treatment Coverage (All Forms)60
Reach-32017e_inc_numEstimated number of incident cases (all forms)6,895,200
Reach-42017(conf_rrmdr+all_conf_xdr)/(e_inc_rr_num)Drug Resistant TB Treatment Coverage33
Reach-42017e_inc_rr_numEstimated incidence of rifampicin resistant TB298,530
Reach-92014(hivtest+newrel_hivtest)/c_newincNotified new and relapse TB cases with documented HIV status59
Reach-92014hivtestTB patients (new and re-treatment) with an HIV test result recorded in the TB register2,203,144
Reach-92017newrel_hivtestNumber of new and relapse TB patients tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis2,525,226
Reach-92014hivtest_posNumber of new and relapse TB patients recorded as HIV-positive429,761
Reach-92017newrel_hivposTB patients recorded as HIV positive362,053
Reach-92017tbhiv_diedOutcomes for HIV-positive TB cases, all types: died0
Reach-92017hivtest+newrel_hivtestTB Cases with Documented HIV Status2,525,226
Reach-92017hivtest_pos+newrel_hivposPatients with TB-HIV Co-infection362,053
Reach-102017rdxsurvey_newinc_rdx/rdxsurvey_newincTB patients tested using a WHO-recommended rapid test that provides a RR result at the time of diagnosis0
Reach-102017rdxsurvey_newincNew and relapse cases whose medical records or treatment cards were included in the survey0
Reach-102017rdxsurvey_newinc_rdxAmong the cases reported in rdxsurvey_newinc the number tested using a WHO-recommended rapid diagnostic (such as Xpert MTB/RIF) at the time of TB diagnosis0
Reach-112017heardoftbPercentage who have heard of TB0
Reach-112017spreadbycoughingPercentage who report that TB is spread through the air by coughing0
Reach-112017tbcanbecuredPercentage who believe that TB can be cured0
Reach-112017keeptbsecretPercentage who would want a family members TB kept secret0
Reach-12.12017(rdst_new)/(new_labconf)Drug Susceptibility Testing Coverage55
Reach-12.12017new_clindxNew pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB)1,400,021
Reach-12.12017new_epNew extrapulmonary cases (bacteriologically confirmed or clinically diagnosed)570,143
Reach-12.12017new_labconfNew pulmonary bacteriologically confirmed TB cases1,894,957
Reach-12.12017rdst_newTB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin1,044,247
Reach-12.12017ret_rel_epRelapse extrapulmonary cases (bacteriologically confirmed or clinically diagnosed)11,816
Reach-12.12017ret_rel_clindxRelapse pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician)57,755
Reach-12.12017ret_rel_labconfRelapse pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics)175,512
Cure Indicators
IndicatorYearVariableDefinitionValue
Cure-12016newrel_cohOutcomes for all new and relapse cases: cohort size3,959,244
Cure-12016newrel_succNumber of TB cases successfully treated (all forms)3,142,061
Cure-12016newrel_succ / newrel_cohPercent of TB Cases Successfully Treated79
Cure-22015mdr_cohOutcomes for MDR-TB cases: cohort size62,700
Cure-22015mdr_succNumber of MDR-TB cases successfully treated (all forms)33,454
Cure-22015(mdr_succ+xdr_succ) / (mdr_coh+xdr_coh)Drug-resistant TB Treatment Success52
Cure-22015mdr_succ+xdr_succNumber Drug Resistant TB Cases Successfully Treated34,756
Cure-22015xdr_cohOutcomes for XDR-TB cases: cohort size4,053
Cure-22015xdr_succOutcomes for XDR-TB cases: treatment success (Cured or treatment completed)1,302
Prevent Indicators
IndicatorYearVariableDefinitionValue
Prevent-1.12017e_prevtx_eligibleEstimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy903,700
Prevent-1.12017newinc_con04_prevtxNumber of children aged under 5 started on TB preventive therapy who are household contacts of bacteriologically-confirmed new and relapse TB cases notified206,012
Prevent-1.12017newinc_con04_prevtx / e_prevtx_eligiblePercent TB Preventive Treatment among Children under-523
Prevent-1.22017hiv_iptPeople living with HIV newly enrolled in HIV care who started treatment for latent TB infection591,270
Prevent-1.22017hiv_ipt_reg_allPeople living with HIV currently enrolled in HIV care who started treatment for latent TB infection315,894
Prevent-1.22017hiv_ipt + hiv_ipt_reg_allNumber of PLHIV newly enrolled in clinical care who initiate TPT907,164
Prevent-1.22014hiv_regTotal number of people registered as HIV-positive regardless of year of diagnosis. (Total number of adults and children enrolled in HIV care; includes everyone in the HIV care and/or ART register)9,654,095
Prevent-1.22017hiv_reg_newNumber of adults and children newly enrolled in HIV care during the year.0
Prevent-1.22014(hiv_ipt + hiv_ipt_reg_all) / (hiv_reg)Percent TB Preventive Treatment among PLHIV9
Prevent-3.12017hcw_tb_infectedNumber of health-care workers who had TB1,747
Prevent-3.12017hcw_totTotal number of health-care workers who were working in the country in the public and private sector2,961,568
Prevent-3.12017hcw_tb_infected / hcw_tot% of HCWs screened for active TB disease (frequency of measurement based on policy)0
Commitment Indicators
IndicatorYearVariableDefinitionValue
Self Reliance-12018budget_totTotal budget required (US Dollars)2,456,526,019
Self Reliance-12018cf_tot_sourcesTotal expected funding from all sources (US Dollars)1,635,053,904
Self Reliance-12018cf_tot_sources / budget_totAmount of funds government has made available for TB NTP by the total amount needed in the TB NTP on an annual basis67
Self Reliance-12018cf_tot_sources / c_newincFinancing Per TB Patient410
Self Reliance-22018cf_tot_domesticExpected funding from domestic sources, including loans (US Dollars)1,003,164,647
Self Reliance-22018cf_tot_domestic / budget_totAmount of domestic financing for TB by the total amount of financing in a country41
Self Reliance-22018cf_tot_domestic / cf_tot_sourcesPercent of total funds required for NTP funded through domestic sources61
Self Reliance-52017exp_fldActual expenditure on drugs to treat drug-susceptible TB (US Dollars)138,745,501
Self Reliance-52017exp_labActual expenditure on laboratory infrastructure, equipment and supplies (US Dollars)183,451,347
Self Reliance-52017exp_sldActual expenditure on drugs to treat drug-resistant TB (US Dollars)135,519,018
Self Reliance-52017rcvd_fldFunding received for drugs to treat drug-susceptible TB (US Dollars)148,227,785
Self Reliance-52017rcvd_labFunding received for laboratory infrastructure, equipment and supplies (US Dollars)193,164,969
Self Reliance-52017rcvd_sldFunding received for drugs to treat drug-resistant TB (US Dollars)143,765,548
Self Reliance-52017 (rcvd_fld + rcvd_lab + rcvd_sld)-(exp_fld + exp_lab + exp_sld)Government expenditures on essential TB program supplies during past year27,442,436
Self Reliance-52017 (rcvd_fld + rcvd_lab + rcvd_sld)-(exp_fld + exp_lab + exp_sld)/ (exp_fld + exp_lab + exp_sld)Percent Government expenditures on essential TB program supplies during past year6